Current Paradigms of Tolerogenic Dendritic Cells and Clinical Implications for Systemic Lupus Erythematosus

Ritprajak, Patcharee; Kaewraemruaen, Chamraj; Hirankarn, Nattiya

doi:10.3390/cells8101291

Cited by 28 publications

(28 citation statements)

References 181 publications

(248 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there is a large body of literature from preclinical models that confirms that DCreg can induce antigen-specific T cell tolerance in vivo (50,65,(81)(82)(83), the collective literature addressing the function of human DCreg is less robust. Most studies with human DCreg have been restricted to showing that these DC only poorly activate allogeneic T cell responses in vitro (50).…”

Section: Dcreg Induce Differentiation Of Regulatory T Cellsmentioning

confidence: 99%

Regulatory Dendritic Cells, T Cell Tolerance, and Dendritic Cell Therapy for Immunologic Disease

2021

View full text Add to dashboard Cite

Dendritic cells (DC) are antigen-presenting cells that can communicate with T cells both directly and indirectly, regulating our adaptive immune responses against environmental and self-antigens. Under some microenvironmental conditions DC develop into anti-inflammatory cells which can induce immunologic tolerance. A substantial body of literature has confirmed that in such settings regulatory DC (DCreg) induce T cell tolerance by suppression of effector T cells as well as by induction of regulatory T cells (Treg). Many in vitro studies have been undertaken with human DCreg which, as a surrogate marker of antigen-specific tolerogenic potential, only poorly activate allogeneic T cell responses. Fewer studies have addressed the abilities of, or mechanisms by which these human DCreg suppress autologous effector T cell responses and induce infectious tolerance-promoting Treg responses. Moreover, the agents and properties that render DC as tolerogenic are many and varied, as are the cells’ relative regulatory activities and mechanisms of action. Herein we review the most current human and, where gaps exist, murine DCreg literature that addresses the cellular and molecular biology of these cells. We also address the clinical relevance of human DCreg, highlighting the outcomes of pre-clinical mouse and non-human primate studies and early phase clinical trials that have been undertaken, as well as the impact of innate immune receptors and symbiotic microbial signaling on the immunobiology of DCreg.

show abstract

Section: Dcreg Induce Differentiation Of Regulatory T Cellsmentioning

confidence: 99%

Regulatory Dendritic Cells, T Cell Tolerance, and Dendritic Cell Therapy for Immunologic Disease

2021

View full text Add to dashboard Cite

show abstract

“…Their role is to inhibit effector and autoreactive T cells and trigger Treg development. As a consequence, they play a main role in inducing immune tolerance, resolution of ongoing immune responses, and prevention of autoimmunity [172,173].…”

Section: Inducing Tolerogenic Dendritic Cellsmentioning

confidence: 99%

“…An increasing body of data indicates that tolerogenic DCs could be promising therapeutic targets in the treatment of autoimmune diseases [172,174]. One of the approaches is to generate ex vivo tolerogenic DCs for DC-based immunotherapy [175,176].…”

Section: Inducing Tolerogenic Dendritic Cellsmentioning

confidence: 99%

A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases

Martı́nez

Juarranz

Gutiérrez‐Cañas

et al. 2019

IJMS

View full text Add to dashboard Cite

The neuroendocrine and immune systems are coordinated to maintain the homeostasis of the organism, generating bidirectional communication through shared mediators and receptors. Vasoactive intestinal peptide (VIP) is the paradigm of an endogenous neuropeptide produced by neurons and endocrine and immune cells, involved in the control of both innate and adaptive immune responses. Exogenous administration of VIP exerts therapeutic effects in models of autoimmune/inflammatory diseases mediated by G-protein-coupled receptors (VPAC1 and VPAC2). Currently, there are no curative therapies for inflammatory and autoimmune diseases, and patients present complex diagnostic, therapeutic, and prognostic problems in daily clinical practice due to their heterogeneous nature. This review focuses on the biology of VIP and VIP receptor signaling, as well as its protective effects as an immunomodulatory factor. Recent progress in improving the stability, selectivity, and effectiveness of VIP/receptors analogues and new routes of administration are highlighted, as well as important advances in their use as biomarkers, contributing to their potential application in precision medicine. On the 50th anniversary of VIP’s discovery, this review presents a spectrum of potential clinical benefits applied to inflammatory and autoimmune diseases.

show abstract

“…Additionally, many reports focus on cell therapy in organ transplantation, including mesenchymal stem cells (MSC), regulatory macrophages (Mreg), tolerogenic dendritic cells (Tol-DC), and regulatory T (Treg) and B (Breg) cells ( 8 – 11 ). Herein, our attention is focused on Tol-DC, which show immunoregulatory functions in autoimmune diseases ( 12 ), infections ( 13 ), and cancers ( 14 ) as well as organ transplant issues ( 8 ). We review their features, ex vivo generation, and clinical applications and discuss their diverse effects on organ transplantation.…”

Section: Introductionmentioning

confidence: 99%

Tolerogenic Dendritic Cells: The Pearl of Immunotherapy in Organ Transplantation

et al. 2020

View full text Add to dashboard Cite

Over a half century, organ transplantation has become an effective method for the treatment of end-stage visceral diseases. Although the application of immunosuppressants (IS) minimizes the rate of allograft rejection, the common use of IS bring many adverse effects to transplant patients. Moreover, true transplant tolerance is very rare in clinical practice. Dendritic cells (DCs) are thought to be the most potent antigen-presenting cells, which makes a bridge between innate and adaptive immunity. Among their subsets, a small portion of DCs with immunoregulatory function was known as tolerogenic DC (Tol-DC). Previous reports demonstrated the ability of adoptively transferred Tol-DC to approach transplant tolerance in animal models. In this study, we summarized the properties, ex vivo generation, metabolism, and clinical attempts of Tol-DC. Tol-DC is expected to become a substitute for IS to enable patients to achieve immune tolerance in the future.

show abstract

Current Paradigms of Tolerogenic Dendritic Cells and Clinical Implications for Systemic Lupus Erythematosus

Cited by 28 publications

References 181 publications

Regulatory Dendritic Cells, T Cell Tolerance, and Dendritic Cell Therapy for Immunologic Disease

Regulatory Dendritic Cells, T Cell Tolerance, and Dendritic Cell Therapy for Immunologic Disease

A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases

Tolerogenic Dendritic Cells: The Pearl of Immunotherapy in Organ Transplantation

Contact Info

Product

Resources

About